Zhaoke Ophthalmology’s Bimatoprost Eye Drop (晶贝清®) Obtains Regulatory Approval for Commercialization

Zhaoke Ophthalmology Announces 2024 Interim Results

Zhaoke Ophthalmology Obtains IND Approval for Phase III Trial of CsA Ophthalmic Gel and Completes the Last Patient Last Visit in its Phase III China CHAMP Trial of NVK002

Zhaoke Ophthalmology Partners with Eye Valley to Jointly Establish the “Eye Valley-Zhaoke Ophthalmology Innovative Ophthalmic Drugs Research Institute”

Zhaoke Ophthalmology Announces 2023 Annual Results:First Annual Sales Revenue Recognized Solid Progress Made in Key Clinical Programs